Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
.
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
..
Date of Report:   April 29, 2019
(Date of earliest event reported)
 
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
 
Commission File Number: 1-7928
.
Delaware
 
94-1381833
(State or other jurisdiction of incorporation)
 
(I.R.S. Employer Identification No.)
1000 Alfred Nobel Dr.
Hercules, California 94547
(Address of principal executive offices, including zip code)
(510) 724-7000
(Registrant’s telephone number, including area code).
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
 
Emerging growth company   ¨
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 
 
 
 
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
 
 
 
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 per share
 
BIO
 
New York Stock Exchange
Class B Common Stock, Par Value $0.0001 per share
 
BIOb
 
New York Stock Exchange





ITEM 5.07
Submission of Matters to a Vote of Security Holders.
 
Bio-Rad Laboratories, Inc. (the “Company”) held its Annual Meeting of Stockholders on April 29, 2019. The matters voted upon at the meeting and the results of those votes are set forth below.


1. Each of the nominated directors was elected and received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows:
 
 
 
 
 
 
 
Class of
 
 
 
 
 
Common Stock
Votes
Votes
Votes
Broker
 
to Elect
For
Against
Abstaining
Non-Votes
 
 
 
 
 
 
Melinda Litherland
Class A
19,096,937
996,513
7,990
 
1,627,967
Arnold A. Pinkston
Class A
19,515,354
579,135
6,951
 
1,627,967
Jeffrey L. Edwards
Class B
4,909,811
659
—
 
125,873
Gregory K. Hinckley
Class B
4,909,811
659
—
 
125,873
Alice N. Schwartz
Class B
4,909,035
1,435
—
 
125,873
Norman Schwartz
Class B
4,908,755
1,715
—
 
125,873
 
2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2019 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:
 
Votes
Votes
Votes
Broker
For
Against
Abstaining
Non-Votes
7,173,989
23,975
11,319
—






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
 
 
BIO-RAD LABORATORIES, INC.
 
 
 
 
 
Date:
May 2, 2019
 
By:
/s/ Timothy S. Ernst
 
 
 
 
Timothy S. Ernst
 
 
 
 
Executive Vice President, General Counsel and Secretary